Immunogenicity of long-lasting recombinant factor VIII products

Cellular Immunology

Volumn 301, Issue , 2016, Pages 40-48

  Ing, Mathieu ^a,b,c   Gupta, Nimesh ^d   Teyssandier, Maud ^a,b,c   Maillère, Bernard ^e   Pallardy, Marc ^f   Delignat, Sandrine ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^e CEA SACLAY   (France)

^f INSERM   (France)

Author keywords

Albumin fusion; Coagulation factor; Factor VIII; Fc fusion; Hemophilia; Immunogenicity; Long lasting; PEGylation

Indexed keywords

EPITOPE; ETHYLENE GLYCOL; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; HYBRID PROTEIN;

DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; HALF LIFE TIME; IMMUNOLOGY; METABOLISM;

FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 84959232861     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.12.006     Document Type: Review

References (83)

1. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:715-725. 10.1038/nri2155.
2. Dumont J.A., Liu T., Low S.C., Zhang X., Kamphaus G., Sakorafas P., et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012, 119:3024-3030. 10.1182/blood-2011-08-367813.
3. Powell J.S., Josephson N.C., Quon D., Ragni M.V., Cheng G., Li E., et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012, 119:3031-3037. 10.1182/blood-2011-09-382846.
4. Shapiro A.D., Ragni M.V., Kulkarni R., Oldenberg J., Srivastava A., Quon D.V., et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J. Thromb. Haemost. 2014, 12:1788-1800. 10.1111/jth.12723.
5. Mahlangu J., Powell J.S., Ragni M.V., Chowdary P., Josephson N.C., Pabinger I., et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014, 123:317-325. 10.1182/blood-2013-10-529974.
6. Young G., Mahlangu J., Kulkarni R., Nolan B., Liesner R., Pasi J., et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J. Thromb. Haemost. 2015, 13:967-977. 10.1111/jth.12911.
7. Gouw S.C., van der Bom J.G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-4654. 10.1182/blood-2006-11-056291.
8. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies. mAbs 2010, 2:256-265.
9. Guyre P.M., Graziano R.F., Goldstein J., Wallace P.K., Morganelli P.M., Wardwell K., et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol. Immunother. 1997, 45:146-148.
10. Konduru K., Bradfute S.B., Jacques J., Manangeeswaran M., Nakamura S., Morshed S., et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 2011, 29:2968-2977. 10.1016/j.vaccine.2011.01.113.
11. Pincetic A., Bournazos S., DiLillo D.J., Maamary J., Wang T.T., Dahan R., et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 2014, 15:707-716. 10.1038/ni.2939.
12. Krishnamoorthy S., Liu T., Drager D., Patarroyo-White S., Chhabra E.S., Peters S., et al. Recombinant factor VIII Fc (rFVIIIFc) Fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell. Immunol. 2016, 301:30-39.
13. Navarrete A., Dasgupta S., Delignat S., Caligiuri G., Christophe O.D., Bayry J., et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J. Thromb. Haemost. 2009, 7:1816-1823. 10.1111/j.1538-7836.2009.03571.x.
14. van der Flier A., Liu Z., Tan S., Chen K., Drager D., Liu T., et al. FcRn rescues recombinant factor VIII Fc fusion protein from a VWF independent FVIII clearance pathway in mouse hepatocytes. PLoS ONE 2015, 10:e0124930. 10.1371/journal.pone.0124930.
15. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640-5649. 10.1182/blood-2012-01-380121.
16. Nimmerjahn F., Ravetch J.V. Fc gamma receptors: old friends and new family members. Immunity 2006, 24:19-28. 10.1016/j.immuni.2005.11.010.
17. Desai D.D., Harbers S.O., Flores M., Colonna L., Downie M.P., Bergtold A., et al. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J. Immunol. Baltimore Md 2007, 1950(178):6217-6226.
18. Horton H.M., Chu S.Y., Ortiz E.C., Pong E., Cemerski S., Leung I.W.L., et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. Baltimore Md 2011, 1950(186):4223-4233. 10.4049/jimmunol.1003412.
19. Werwitzke S., Vollack N., von Hornung M., Kalippke K., Kutzschbach J., Trummer A., et al. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Thromb. Haemost. 2015, 114. 10.1160/TH14-06-0535.
20. De Groot A.S., Cousens L., Mingozzi F., Martin W. Tregitope peptides: the active pharmaceutical ingredient of IVIG?. Clin. Dev. Immunol. 2013, 2013:493138. 10.1155/2013/493138.
21. Hui D.J., Basner-Tschakarjan E., Chen Y., Davidson R.J., Buchlis G., Yazicioglu M., et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol. Ther. J. Am. Soc. Gene Ther. 2013, 21:1727-1737. 10.1038/mt.2013.166.
22. Heath W.R., Carbone F.R. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat. Immunol. 2013, 14:978-985. 10.1038/ni.2680.
23. Shklovskaya E., O'Sullivan B.J., Ng L.G., Roediger B., Thomas R., Weninger W., et al. Langerhans cells are precommitted to immune tolerance induction. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18049-18054. 10.1073/pnas.1110076108.
24. Grubb J.H., Vogler C., Tan Y., Shah G.N., MacRae A.F., Sly W.S. Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8375-8380. 10.1073/pnas.0803715105.
25. Gupta N., Culina S., Meslier Y., Dimitrov J., Arnoult C., Delignat S., et al. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci. Trans. Med. 2015, 7:275ra21. 10.1126/scitranslmed.aaa1957.
26. Sleep D., Cameron J., Evans L.R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830, 2013:5526-5534. 10.1016/j.bbagen.2013.04.023.
27. Subramanyam M. Immunogenicity of biotherapeutics-an overview. J. Immunotoxicol. 2006, 3:151-156. 10.1080/15476910600845740.
28. Neumiller J.J. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin. Ther. 2011, 33:528-576. 10.1016/j.clinthera.2011.04.024.
29. Pratley R.E., Nauck M.A., Barnett A.H., Feinglos M.N., Ovalle F., Harman-Boehm I., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diab. Endocrinol. 2014, 2:289-297. 10.1016/S2213-8587(13)70214-6.
30. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb. Res. 2013, 131(Suppl. 2):S2-S6. 10.1016/S0049-3848(13)70150-6.
31. Weimer T., Wormsbächer W., Kronthaler U., Lang W., Liebing U., Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemost. 2008, 99:659-667. 10.1160/TH07-08-0525.
32. Golor G., Bensen-Kennedy D., Haffner S., Easton R., Jung K., Moises T., et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J. Thromb. Haemost. 2013, 11:1977-1985. 10.1111/jth.12409.
33. Martinowitz U., Lissitchkov T., Lubetsky A., Jotov G., Barazani-Brutman T., Voigt C., et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 2015, 10.1111/hae.12721.
34. J.S. Powell, Novel Approaches for Hemophilia Treatment, Medscape. (2015). (accessed October 22, 2015). http://www.medscape.com/viewarticle/841623.
35. Lim S.I., Hahn Y.S., Kwon I. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. J. Control. Release 2015, 207:93-100. 10.1016/j.jconrel.2015.04.004.
36. Caraceni P., Tufoni M., Bonavita M.E. Clinical use of albumin. Blood Transfus. Trasfus. Sangue. 2013, 11(Suppl. 4):s18-s25. 10.2450/2013.005s.
37. Weber C.A., Mehta P.J., Ardito M., Moise L., Martin B., De Groot A.S. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv. Drug Deliv. Rev. 2009, 61:965-976. 10.1016/j.addr.2009.07.001.
38. Kolbus D., Wigren M., Ljungcrantz I., Söderberg I., Alm R., Björkbacka H., et al. Immunization with cationized BSA inhibits progression of disease in ApoBec-1/LDL receptor deficient mice with manifest atherosclerosis. Immunobiology 2011, 216:663-669. 10.1016/j.imbio.2010.11.003.
39. Saifer M.G., Somack R., Williams L.D. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol. Adv. Exp. Med. Biol. 1994, 366:377-387.
40. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-417.
41. Hamidi M., Azadi A., Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006, 13:399-409. 10.1080/10717540600814402.
42. Mei B., Pan C., Jiang H., Tjandra H., Strauss J., Chen Y., et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010, 116:270-279. 10.1182/blood-2009-11-254755.
43. Coyle T.E., Reding M.T., Lin J.C., Michaels L.A., Shah A., Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J. Thromb. Haemost. 2014, 12:488-496.
44. Turecek P.L., Bossard M.J., Graninger M., Gritsch H., Höllriegl W., Kaliwoda M., et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hämostaseologie 2012, 32(Suppl. 1):S29-S38.
45. Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015, 126:1078-1085. 10.1182/blood-2015-03-630897.
46. Stennicke H.R., Kjalke M., Karpf D.M., Balling K.W., Johansen P.B., Elm T., et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013, 121:2108-2116. 10.1182/blood-2012-01-407494.
47. Pastoft A.E., Ezban M., Tranholm M., Lykkesfeldt J., Lauritzen B. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. Haemophilia 2013, 19:913-919. 10.1111/hae.12198.
48. Tiede A., Brand B., Fischer R., Kavakli K., Lentz S.R., Matsushita T., et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J. Thromb. Haemost. 2013, 11:670-678. 10.1111/jth.12161.
49. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
50. Paz J.X.P. PEGylated FVIII exhibits reduced immunogenicity in hemophilia A mice and in vitro in human cells. Haemophilia 2012, 18.
51. Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L., et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. Biol. Fate Chem. 2007, 35:9-16. 10.1124/dmd.106.012419.
52. Bendele A., Seely J., Richey C., Sennello G., Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 1998, 42:152-157. 10.1093/toxsci/42.2.152.
53. Rudmann D.G., Alston J.T., Hanson J.C., Heidel S. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol. 2013, 41:970-983. 10.1177/0192623312474726.
54. Baumann A., Tuerck D., Prabhu S., Dickmann L., Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?. Drug Discov. Today 2014, 19:1623-1631. 10.1016/j.drudis.2014.06.002.
55. Viau A.T., Abuchowski A., Greenspan S., Davis F.F. Safety evaluation of free radical scavengers PEG-catalase and PEG-superoxide dismutase. J. Free Radic. Biol. Med. 1986, 2:283-288.
56. Young M.A., Malavalli A., Winslow N., Vandegriff K.D., Winslow R.M. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Trans. Res. J. Lab. Clin. Med. 2007, 149:333-342. 10.1016/j.trsl.2006.09.007.
57. Stidl R., Fuchs S., Bossard M., Siekmann J., Turecek P.L., Putz M. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates. Haemophilia 2015, 10.1111/hae.12762.
58. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 2012, 9:1319-1323. 10.1517/17425247.2012.720969.
59. Richter A.W., Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 1983, 70:124-131.
60. Mima Y., Hashimoto Y., Shimizu T., Kiwada H., Ishida T. Anti-PEG IgM Is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol. Pharm. 2015, 12:2429-2435. 10.1021/acs.molpharmaceut.5b00144.
61. Tillmann H., Ganson N.J., Patel K., Thompson A.J., Abdelmalek M., Moody T., et al. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J. Hepatol. 2010, 52(Suppl. 1):S129. 10.1016/S0168-8278(10)60309-1.
62. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111. 10.1002/cncr.22739.
63. Shimizu T., Mima Y., Hashimoto Y., Ukawa M., Ando H., Kiwada H., et al. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells. Immunobiology 2015, 220:1151-1160. 10.1016/j.imbio.2015.06.005.
64. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317. 10.1016/j.jconrel.2005.04.003.
65. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 2013, 172:38-47. 10.1016/j.jconrel.2013.07.026.
66. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250. 10.1016/j.jconrel.2006.08.001.
67. Abu A.S., Lila M., Ichihara T., Shimizu T., Ishida H. Kiwada, Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome. Biol. Pharm. Bull. 2013, 36:1842-1848.
68. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Uehara Y., Ishida T., et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2010, 3:1-11. 10.3390/pharmaceutics3010001.
69. Koide H., Asai T., Hatanaka K., Akai S., Ishii T., Kenjo E., et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm. 2010, 392:218-223. 10.1016/j.ijpharm.2010.03.022.
70. Hashimoto Y., Shimizu T., Abu Lila A.S., Ishida T., Kiwada H. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Biol. Pharm. Bull. 2015, 38:417-424. 10.1248/bpb.b14-00653.
71. Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46:225-232. 10.1016/j.molimm.2008.08.276.
72. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030. 10.1016/j.addr.2011.06.017.
73. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
74. van Helden P.M., Unterthurner S., Hermann C., Schuster M., Ahmad R.U., Schiviz A.N., et al. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood 2011, 118:3698-3707. 10.1182/blood-2010-11-316521.
75. Castro-Núñez L., Dienava-Verdoold I., Herczenik E., Mertens K., Meijer A.B. Shear stress is required for the endocytic uptake of the factor VIII-von Willebrand factor complex by macrophages. J. Thromb. Haemost. 2012, 10:1929-1937. 10.1111/j.1538-7836.2012.04860.x.
76. van Schooten C.J., Shahbazi S., Groot E., Oortwijn B.D., van den Berg H.M., Denis C.V., et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008, 112:1704-1712. 10.1182/blood-2008-01-133181.
77. Skupsky J., Zhang A.-H., Su Y., Scott D.W. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009, 114:4741-4748. 10.1182/blood-2008-10-186452.
78. Gangadharan B., Delignat S., Ollivier V., Gupta N., Mackman N., Kaveri S.V., et al. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. J. Thromb. Haemost. 2014, 12:2065-2069. 10.1111/jth.12740.
79. Dasgupta S., Navarrete A.-M., Bayry J., Delignat S., Wootla B., André S., et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8965-8970. 10.1073/pnas.0702120104.
80. Repessé Y., Dasgupta S., Navarrete A.-M., Delignat S., Kaveri S.V., Lacroix-Desmazes S. Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. J. Allergy Clin. Immunol. 2012, 129:1172-1173. (author reply 1174-1175). 10.1016/j.jaci.2012.01.048.
81. Yanover C., Jain N., Pierce G., Howard T.E., Sauna Z.E. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat. Biotechnol. 2011, 29:870-873. 10.1038/nbt.2002.
82. Pashov A.D., Calvez T., Gilardin L., Maillère B., Repessé Y., Oldenburg J., et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia 2014, 20:176-184. 10.1111/hae.12276.
83. Shepherd A.J., Skelton S., Sansom C.E., Gomez K., Moss D.S., Hart D.P. A large-scale computational study of inhibitor risk in non-severe haemophilia A. Br. J. Haematol. 2015, 168:413-420. 10.1111/bjh.13131.